Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT07365358
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT07365358
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07365358. Randomized; no masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2027-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
- Acronym
- EMPAGO
- Condition
- Diabete Type 2
- Intervention (Drug)
- empagliflozin 10mg
- Intervention (Drug)
- Glimepiride 1mg
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct07365358- Content hash
dc2812737c7a2ee24d337ab9d4e7027d951a0d342d4754101eb2e6b9a38e6116